Purnamasidhi Cokorda Agung Wahyu, Suega Ketut, Bakta I Made
Division of Hematology and Medical Oncology, Internal Medicine Department Udayana University, Sanglah General Hospital Denpasar, Denpasar, Bali, Indonesia.
Open Access Maced J Med Sci. 2019 Jun 30;7(12):1984-1986. doi: 10.3889/oamjms.2019.470.
Non-Hodgkin Lymphoma (NHL) is a malignant haematological disease originates in the lymphocytes, caused by an abnormality in lymphocytes development which forms a tumour and may become cancer. Chemotherapy is the main treatment modality for aggressive lymphoma, but only a few patients achieve remission. Several factors such as age, clinical stadium, number of extranodal regions, and Lactate Dehydrogenase (LDH) level played a role in determining response to chemotherapy.
To measure the association between LDH levels to prognosis of NHL in elderly patients who treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in Sanglah General Hospital.
This study used a retrospective descriptive study on elderly NHL patients in Sanglah General Hospital from January until December 2014. The evaluation was measured using the IPI score to determine the prognosis of patients. Demographic data, the stadium, extranodal region, LDH level, and response to chemotherapy were recorded.
Twenty-five patients were included in the study. The age ranged was between 61-76 years old (Mean 65,68 ± 4,7 years; Median 65 years). The number of male patients was 19 (76%). Diffuse Large B-Cell Lymphoma (DLBCL) is the most common histopathological structure observed on the patients (68%). LDH levels were normal in 51.6% of the patients and considered high in the rests (48.4%). Results of the chemotherapy were a good response in 72.2%. Compared to the patients who showed complete response to chemotherapy, patients with no response (partial response and progression) had significantly higher levels of LDH (OR: 13,1; 95% CI: 1,36-126,30; p = 0,001).
Non-Hodgkin Lymphoma in elderly patients with no response to chemotherapy had significantly higher levels of LDH than patients with complete response.
非霍奇金淋巴瘤（NHL）是一种起源于淋巴细胞的恶性血液疾病，由淋巴细胞发育异常导致肿瘤形成，且可能发展为癌症。化疗是侵袭性淋巴瘤的主要治疗方式，但只有少数患者能实现缓解。年龄、临床分期、结外区域数量以及乳酸脱氢酶（LDH）水平等多种因素在决定化疗反应中发挥作用。
在桑格拉总医院，测量接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松龙化疗的老年患者中，LDH水平与NHL预后之间的关联。
本研究对2014年1月至12月在桑格拉总医院的老年NHL患者进行回顾性描述性研究。使用国际预后指数（IPI）评分来评估患者的预后。记录人口统计学数据、分期、结外区域、LDH水平以及化疗反应。
25名患者纳入研究。年龄范围在61 - 76岁之间（平均65.68±4.7岁；中位数65岁）。男性患者19名（76%）。弥漫性大B细胞淋巴瘤（DLBCL）是患者中最常见的组织病理学结构（68%）。51.6%的患者LDH水平正常，其余患者（48.4%）被认为LDH水平较高。化疗结果显示72.2%的患者反应良好。与化疗完全缓解的患者相比，无反应（部分缓解和病情进展）的患者LDH水平显著更高（比值比：13.1；95%置信区间：1.36 - 126.30；p = 0.001）。
对化疗无反应的老年非霍奇金淋巴瘤患者的LDH水平显著高于完全缓解的患者。
